Skip to main content

Thrombotic Thrombocytopenic Purpura (TTP)

0
Pipeline Programs
2
Companies
9
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
2 programs
Recombinant ADAMTS13N/A2 trials
TAK-755PHASE_35 trials
Active Trials
NCT07429942Not Yet Recruiting94Est. May 2026
NCT06441578Recruiting40Est. Sep 2032
NCT05770219Approved For Marketing
+4 more trials
Octapharma
OctapharmaAustria - Vienna
1 program
UniplasPHASE_31 trial
Active Trials
NCT00411801Terminated8Est. Feb 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
TakedaTAK-755
TakedaTAK-755
OctapharmaUniplas
TakedaTAK-755
TakedaTAK-755
TakedaTAK-755
TakedaRecombinant ADAMTS13
TakedaRecombinant ADAMTS13

Clinical Trials (9)

Total enrollment: 541 patients across 9 trials

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Start: Apr 2021Est. completion: Mar 202777 patients
Phase 3Active Not Recruiting

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Start: Oct 2017Est. completion: May 202452 patients
Phase 3Completed

Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

Start: May 2007Est. completion: Feb 20088 patients
Phase 3Terminated

A Study of TAK-755 in Adults With Acute Ischemic Stroke

Start: Apr 2026Est. completion: Dec 2027222 patients
Phase 2Recruiting

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Start: Mar 2023Est. completion: Apr 202629 patients
Phase 2Completed

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease

Start: Oct 2019Est. completion: Oct 202219 patients
Phase 1Completed

Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

N/AApproved For Marketing
NCT07429942TakedaRecombinant ADAMTS13

A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program

Start: Apr 2026Est. completion: May 202694 patients
N/ANot Yet Recruiting
NCT06441578TakedaRecombinant ADAMTS13

A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Start: May 2024Est. completion: Sep 203240 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 541 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.